The Motley Fool Discussion Boards

Previous Page

Social Clubs / The World is Flat


Subject:  Re: Peak Gene Therapy? Date:  6/19/2019  12:50 AM
Author:  Fuma102 Number:  242 of 252

Sangamo has always been a dog. It's been around TWO DECADES and has changed targets a bunch. Sangamo is one of these companies that continues to miss deadlines, fail in trials, yet somehow doesnt go to bagel-town, and 5-10 years later reinvents itself, only to fail again. Geron is another. Novavax another. NKTR is likely going to be on that list. Sangamo was big on peripheral neuropathy for awhile. then onto HIV. then regenerative medicine (I think?) ... poor focus, poor execution, long history of failures.

There are some companies that fade into the background for long enough that the last wave of biotech newbies who got burned have abandoned biotech, only to feast on the next round of newbies.

It's an art, really.

Rulebook #10. If a company has changed therapeutic focus more than twice and doesnt have a marketed drug and has been public more than 5 years, run.
Copyright 1996-2021 trademark and the "Fool" logo is a trademark of The Motley Fool, Inc. Contact Us